NextCure, Inc. (NXTC)
NASDAQ: NXTC · Real-Time Price · USD
0.6153
+0.0648 (11.78%)
Jun 11, 2025, 4:00 PM - Market closed
NextCure Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
43
Market Cap
17.26M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
NXTC News
- 13 days ago - NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025 - GlobeNewsWire
- 5 weeks ago - NextCure Provides Business Update and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - NextCure to Present at 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 3 months ago - NextCure Provides Business Update and Reports Full Year 2024 Financial Results - GlobeNewsWire
- 5 months ago - NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers - GlobeNewsWire
- 6 months ago - NextCure Announces Acceptance of IND Application for LNCB74 - GlobeNewsWire
- 7 months ago - NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference - GlobeNewsWire
- 7 months ago - Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta - GlobeNewsWire